Skip to main content
. Author manuscript; available in PMC: 2012 Sep 14.
Published in final edited form as: JAMA. 2012 Apr 4;307(13):1383–1393. doi: 10.1001/jama.2012.385

Figure 2.

Figure 2

Disease-Free Survival After Treatment With mFOLFOX6 Alone and mFOLFOX6 With Cetuximab in the Wild-Type KRAS, Mutated KRAS, and Wild-Type KRAS and Mutated KRAS With Age <70 and ≥70 Years Patient Groups

mFOLFOX6 indicates the modified sixth version of the leucovorin, fluorouracil, and oxaliplatin regimen; HR, hazard ratio.

HHS Vulnerability Disclosure